MCRB
Seres Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.72
+1.42%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +9.9%
- EBIT
- +23.7%
- EPS
- +69.4%
- Free cash flow
- +15.0%
- Operating cash flow
- +14.5%
Forward estimates
Based on analyst estimates
- Revenue
- +574.7%
- EBITDA
- +64.7%
- EPS
- +16.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- +108.2%
- EBIT
- +22.5%
- Net income
- +103.9%
- EPS
- +103.4%
- Free cash flow
- +100.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026